NCT06946225 2026-01-08ACTengine® IMA203 Combined With mRNA-4203Immatics US, Inc.Phase 1 Recruiting15 enrolled
NCT05492682 2025-09-05START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerValo Therapeutics OyPhase 1 Active not recruiting15 enrolled
NCT03132922 2024-01-22MAGE-A4ᶜ¹º³²T for Multi-TumorAdaptimmunePhase 1 Active not recruiting71 enrolled
NCT03638206 2019-12-11Autologous CAR-T/TCR-T Cell Immunotherapy for MalignanciesShenzhen BinDeBio Ltd.Phase 1/2 Unknown73 enrolled
NCT00154388 2016-11-18Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesNovartisPhase 2 Completed185 enrolled